Mandate

Vinge represented the sellers in the divestment of Fred Holmberg & Co AB

December 31, 2014

Vinge represented the sellers in the divestment of Fred Holmberg & Co AB to Brenntag Nordic AB. Fred Holmberg & Co AB is active within the field of distribution of chemicals, biofuels and products for NOx reduction and has an expected turnover of more than SEK 700 million for 2014. Brenntag is the world leader in chemicals distribution and the acquisition strengthens Brenntag’s presence on the Nordic market.

Vinge’s team consisted of partner Jesper Ottergren together with associate Fredrik Christiansson. In addition, specialist Mathias Lindqvist has assisted with environmental law expertise and partner Pär Remnelid, together with associate Lisa Bourghardt, have assisted with competition law expertise.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026